Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05218642 · ClinicalTrials.gov registry record · Phase 2
To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia
A Phase 2 study, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT05218642: Completed Phase 2 study, sponsored by Suzhou Kintor Pharmaceutical Inc,.
NCT05218642 is a Phase 2 study that has completed, run by Suzhou Kintor Pharmaceutical Inc,. The registered enrollment target is 123 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05218642, a Phase 2 study, has completed, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia.
Primary Outcome
Changes from baseline in non-vellus TAHC (Target Area Hair Counts) in comparison to placebo
Interventions
- DRUG KX- 826 dosed at 2.5mg
- DRUG KX-826 dosed at 5mg
- DRUG Matching placebo to KX-826
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2023-02-13 |
| Phase | Phase 2 |
What the finished NCT05218642 record still lists
NCT05218642 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which KX- 826 dosed at 2.5mg is the first listed.
NCT05218642 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05218642 about?
NCT05218642 is a clinical study titled "To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia". The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia.
What is the current status of trial NCT05218642?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2022-01-31. Estimated completion is 2023-02-13.
What interventions are being tested in trial NCT05218642?
The interventions under investigation include: KX- 826 dosed at 2.5mg (DRUG), KX-826 dosed at 5mg (DRUG), Matching placebo to KX-826 (DRUG).
Who is sponsoring clinical trial NCT05218642?
This trial is sponsored by Suzhou Kintor Pharmaceutical Inc,, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05218642's enrollment target sits among peer trials
123 564th of 2000 higher than 1,436 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI